All In Biotech

Drug Trial Radar · NCT04102462

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 764198 in Healthy Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design) and Effect of Food on the Relative Bioavailability of BI 764198 (Open-label, Randomised, Two-way Cross-over)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Oct 29, 2019

Primary completion

Oct 8, 2020

Study completion Oct 8, 2020

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To investigate safety and tolerability of BI 764198 in healthy male subjects following oral administration of multiple rising doses per day over 14 days and to explore the pharmacokinetics (PK) of BI 764198 after single and multiple oral dosing. In addition, the effect of BI 764198 on the pharmacokinetics of midazolam, given as an oral microdose, will be explored after multiple oral dosing.

Conditions

  • Healthy

Interventions

  • BI 764198Drug

    Capsules

  • Matching placeboDrug

    Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with drug-related adverse eventsTime frame: Up to Day 34

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CRS Clinical Research Services Mannheim GmbH

    Mannheim, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.